SHANGHAI – Under the leadership of CEO Pascal Soriot, AstraZeneca PLC has transformed itself to a pure-play pharmaceutical innovator with a focus on three core therapeutic areas – cardiovascular/metabolic disease, oncology and respiratory/inflammatory disease – and a force in emerging market drug discovery efforts.
As part of that effort, the company announced on Dec. 19 (after this interview was conducted) that it would buy out Bristol-Myers Squibb Co.’s interest in their diabetes alliance, including the drug assets, employees and infrastructure. AstraZeneca will pay $2.7 billion upfront, as well as $1
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?